Biotechnology Assets, S.A. (BME: BST)
Spain
· Delayed Price · Currency is EUR 0.303
+0.008 (2.54%)
Dec 18, 2024, 5:21 PM CET
Biotechnology Assets Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 3.37 | 3.91 | 2.96 | 3.28 | 2.89 | 3.24 | Upgrade
|
| Revenue Growth (YoY) | -1.96% | 32.14% | -9.87% | 13.50% | -10.68% | -87.17% | Upgrade
|
| Cost of Revenue | 0.47 | 0.45 | 0.36 | 0.25 | 0.2 | 0.34 | Upgrade
|
| Gross Profit | 2.9 | 3.46 | 2.59 | 3.04 | 2.7 | 2.9 | Upgrade
|
| Selling, General & Admin | 2.78 | 2.96 | 2.56 | 3.33 | 2.18 | 3.67 | Upgrade
|
| Other Operating Expenses | -0.24 | -4.68 | -0.38 | -0.3 | -0.48 | -0.55 | Upgrade
|
| Operating Expenses | 4.86 | 0.75 | 4.33 | 5.11 | 3.91 | 5.44 | Upgrade
|
| Operating Income | -1.96 | 2.71 | -1.74 | -2.07 | -1.21 | -2.54 | Upgrade
|
| Interest Expense | -0.28 | -0.31 | -0.35 | -0.85 | -0.33 | -0.38 | Upgrade
|
| Interest & Investment Income | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.04 | -0.02 | 0.03 | 0.01 | -0.01 | -0 | Upgrade
|
| EBT Excluding Unusual Items | -2.27 | 2.38 | -2.05 | -2.91 | -1.56 | -2.92 | Upgrade
|
| Asset Writedown | -0.05 | -0.05 | - | - | - | - | Upgrade
|
| Other Unusual Items | 0 | 0 | 0.01 | 0 | 0 | 0 | Upgrade
|
| Pretax Income | -2.32 | 2.32 | -2.04 | -2.91 | -1.55 | -2.92 | Upgrade
|
| Income Tax Expense | 0.73 | 0.75 | -0.1 | 0.1 | 0.15 | 0.09 | Upgrade
|
| Earnings From Continuing Operations | -3.05 | 1.57 | -1.94 | -3.01 | -1.7 | -3.01 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | -6.9 | -7.07 | Upgrade
|
| Net Income to Company | -3.05 | 1.57 | -1.94 | -3.01 | -8.61 | -10.08 | Upgrade
|
| Minority Interest in Earnings | - | -0 | 0 | 0 | 0 | 0 | Upgrade
|
| Net Income | -3.05 | 1.57 | -1.94 | -3.01 | -8.61 | -10.08 | Upgrade
|
| Net Income to Common | -3.05 | 1.57 | -1.94 | -3.01 | -8.61 | -10.08 | Upgrade
|
| Shares Outstanding (Basic) | 64 | 58 | 54 | 46 | 39 | 39 | Upgrade
|
| Shares Outstanding (Diluted) | 64 | 58 | 54 | 46 | 39 | 39 | Upgrade
|
| Shares Change (YoY) | 10.39% | 6.50% | 18.82% | 16.39% | 0.04% | -0.03% | Upgrade
|
| EPS (Basic) | -0.05 | 0.03 | -0.04 | -0.07 | -0.22 | -0.26 | Upgrade
|
| EPS (Diluted) | -0.05 | 0.03 | -0.04 | -0.07 | -0.22 | -0.26 | Upgrade
|
| Free Cash Flow | 0.92 | -0.02 | -0.14 | -1.52 | 8.8 | -22.87 | Upgrade
|
| Free Cash Flow Per Share | 0.01 | -0.00 | -0.00 | -0.03 | 0.22 | -0.58 | Upgrade
|
| Gross Margin | 86.10% | 88.47% | 87.67% | 92.49% | 93.25% | 89.62% | Upgrade
|
| Operating Margin | -57.98% | 69.28% | -58.71% | -63.22% | -41.96% | -78.57% | Upgrade
|
| Profit Margin | -90.49% | 40.27% | -65.70% | -91.80% | -297.64% | -311.45% | Upgrade
|
| Free Cash Flow Margin | 27.39% | -0.56% | -4.90% | -46.29% | 304.47% | -706.54% | Upgrade
|
| EBITDA | -1.72 | 3.72 | -0.71 | -1.04 | -0.17 | -0.48 | Upgrade
|
| EBITDA Margin | -51.03% | 95.23% | -24.04% | -31.79% | -5.85% | -14.68% | Upgrade
|
| D&A For EBITDA | 0.23 | 1.01 | 1.03 | 1.03 | 1.04 | 2.07 | Upgrade
|
| EBIT | -1.96 | 2.71 | -1.74 | -2.07 | -1.21 | -2.54 | Upgrade
|
| EBIT Margin | -57.98% | 69.28% | -58.71% | -63.22% | -41.96% | -78.57% | Upgrade
|
| Effective Tax Rate | - | 32.23% | - | - | - | - | Upgrade
|
| Advertising Expenses | - | 0.04 | 0.01 | 0.05 | 0.03 | 0.02 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.